THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Submission of Matters to a Vote of Security Holders

THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) The 2018 Annual General Meeting of Shareholders (the “Annual Meeting”) of Theravance Biopharma,Inc. (the “Company”) was held on May1, 2018.

(b) Shareholders holding 52,492,984 shares of capital stock, representing 95.79% of the total number of shares outstanding and entitled to vote at the Annual Meeting, were present in person or by proxy at the Annual Meeting. Each of the proposals voted on by the Shareholders at the Annual Meeting was approved.

The nominees listed below were elected ClassI members of the Board of Directors with the respective numbers of shares voted set forth opposite their names:

Nominees

For

Against

Abstain

Broker Non-Votes

Eran Broshy

46,510,482

2,280,017

10,343

3,692,142

Percentage of Shares Voted

95.31

4.67

0.02

Laurie Smaldone Alsup

48,204,151

586,348

10,343

3,692,142

Percentage of Shares Voted

98.78

1.20

0.02

Burton G. Malkiel

46,003,288

2,795,078

2,476

3,692,142

Percentage of Shares Voted

94.26

5.73

0.01

The shareholders ratified the selection by the Audit Committee of the Board of Directors of Ernst& Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018. The voting results are set forth below:

For

Against

Abstain

BrokerNon- Votes

Number of Shares Voted

52,277,477

196,565

18,942

Percentage of Shares Voted

99.59

0.37

0.04

The shareholders adopted a resolution approving a new shareholder rights plan and authorizing the Company’s board of directors to put the shareholder rights plan into effect in the future if and when the board of directors deems appropriate and in the best interests of the Company, which resolution is set forth as Annex A to the Company’s definitive proxy statement on Schedule 14A filed with the United States Securities and Exchange Commission on March21, 2018 (the “Proxy Statement”). The voting results are set forth below:

For

Against

Abstain

BrokerNon- Votes

Number of Shares Voted

25,917,908

22,878,892

4,042

3,692,142

Percentage of Shares Voted

53.11

46.88

0.01

For more information about the foregoing proposals, see the Company’s Proxy Statement.


About THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH)

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

An ad to help with our costs